Latest Breaking News On - John fesko - Page 2 : comparemela.com

Natera's (NTRA) "Overweight" Rating Reiterated at Stephens

Stephens reiterated their overweight rating on shares of Natera (NASDAQ:NTRA – Free Report) in a research report released on Tuesday, Benzinga reports. Stephens currently has a $78.00 price target on the medical research company’s stock. A number of other equities research analysts also recently weighed in on the stock. Piper Sandler lowered their target price […]

Harvest Fund Management Co. Ltd Takes Position in Natera, Inc. (NASDAQ:NTRA)

Harvest Fund Management Co. Ltd acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,001 shares of the medical research company’s stock, valued at approximately $44,000. Several other hedge funds and other institutional investors […]

Natera, Inc. (NASDAQ:NTRA) Insider John Fesko Sells 2,358 Shares

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 2,358 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $65.09, for a total transaction of $153,482.22. Following the sale, the insider now owns 108,494 shares in the company, valued at approximately […]

Natera Announces Real-World Data Collaboration with Merck

Natera, Inc. , a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will.

Natera (NTRA) Announces Real-World Data Collaboration with Merck (MRK)